Clare Yvonne England1,2, Laura Moss3, Matthew Beasley4, Ingrid Haupt-Schott3, Georgia Herbert1, Charlotte Atkinson1. 1. National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, United Kingdom. 2. Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, United Kingdom. 3. Velindre Cancer Centre, Cardiff, United Kingdom. 4. University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Abstract
BACKGROUND: Guidelines suggest that a low iodine diet (LID) is advised prior to radioiodine ablation (RIA) for thyroid cancer. We aim to describe current practice regarding LID advice in the UK, determine uptake of the 2016 UK LID Working Group diet sheet and discover whether there are differences in practice. METHODS: We used an online survey distributed between November 2018 and April 2019 to centres in the UK that administer <sup>131</sup>I. We asked questions on whether a LID is advised, for how long, how advice is presented, whether and how compliance is measured and whether treatment is delayed if LID advice is not followed. RESULTS: Fifty-six clinicians from 47 centres that carry out RIA for thyroid cancer responded. Forty-four centres (94%) advise a LID prior to RIA, the majority for 14 days (82%). Two-thirds of the centres use the UK LID Working Group diet sheet. Patients are told to resume normal eating when <sup>131</sup>I is administered at 17 centres (39%), with 18 (41%) advising waiting for 24-48 h after administration. Most centres (95%) use only a simple question or do not assess compliance. Only 2 (5%) indicate that RIA would be delayed if someone said they had not followed LID advice. CONCLUSIONS: UK practice regarding LID prior to RIA for thyroid cancer is consistent with current guidelines, but non-adherence does not usually delay RIA. The UK Low Iodine Diet Working Group diet sheet is widely recognised and used. Practice could be improved by centres working to harmonise advice on when to restart a normal diet.
BACKGROUND: Guidelines suggest that a low iodine diet (LID) is advised prior to radioiodine ablation (RIA) for thyroid cancer. We aim to describe current practice regarding LID advice in the UK, determine uptake of the 2016 UK LID Working Group diet sheet and discover whether there are differences in practice. METHODS: We used an online survey distributed between November 2018 and April 2019 to centres in the UK that administer <sup>131</sup>I. We asked questions on whether a LID is advised, for how long, how advice is presented, whether and how compliance is measured and whether treatment is delayed if LID advice is not followed. RESULTS: Fifty-six clinicians from 47 centres that carry out RIA for thyroid cancer responded. Forty-four centres (94%) advise a LID prior to RIA, the majority for 14 days (82%). Two-thirds of the centres use the UK LID Working Group diet sheet. Patients are told to resume normal eating when <sup>131</sup>I is administered at 17 centres (39%), with 18 (41%) advising waiting for 24-48 h after administration. Most centres (95%) use only a simple question or do not assess compliance. Only 2 (5%) indicate that RIA would be delayed if someone said they had not followed LID advice. CONCLUSIONS: UK practice regarding LID prior to RIA for thyroid cancer is consistent with current guidelines, but non-adherence does not usually delay RIA. The UK Low Iodine Diet Working Group diet sheet is widely recognised and used. Practice could be improved by centres working to harmonise advice on when to restart a normal diet.
Authors: Anna M Sawka; Irada Ibrahim-Zada; Philip Galacgac; Richard W Tsang; James D Brierley; Shereen Ezzat; David P Goldstein Journal: Thyroid Date: 2010-10 Impact factor: 6.568
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: Maurice J H M Pluijmen; Carmen Eustatia-Rutten; Bernard M Goslings; Marcel P Stokkel; Alberto M Pereira Arias; Michaela Diamant; Johannes A Romijn; Jan W A Smit Journal: Clin Endocrinol (Oxf) Date: 2003-04 Impact factor: 3.478
Authors: M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri Journal: Eur J Nucl Med Mol Imaging Date: 2008-10 Impact factor: 9.236
Authors: Seo Young Sohn; Joon Young Choi; Hye Won Jang; Hye Jeong Kim; Sang Man Jin; Se Won Kim; Sunghwan Suh; Kyu Yeon Hur; Jae Hyeon Kim; Jae Hoon Chung; Sun Wook Kim Journal: Thyroid Date: 2013-06 Impact factor: 6.568
Authors: Petros Perros; Kristien Boelaert; Steve Colley; Carol Evans; Rhordi M Evans; Georgina Gerrard Ba; Jackie Gilbert; Barney Harrison; Sarah J Johnson; Thomas E Giles; Laura Moss; Val Lewington; Kate Newbold; Judith Taylor; Rajesh V Thakker; John Watkinson; Graham R Williams Journal: Clin Endocrinol (Oxf) Date: 2014-07 Impact factor: 3.478
Authors: Bernadette L Dekker; Mirthe H Links; Anneke C Muller Kobold; Linda G Swart-Busscher; Marleen Kars; Judith A P Bons; Adrienne H Brouwers; Thera P Links; Anouk N A van der Horst-Schrivers Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 5.958